Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 13;4:1391. doi: 10.1038/s42003-021-02906-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 7 — a Schematic diagram illustrating the development of EGFR-TKI resistance. b Immunoblotting analysis showing the expression of indicated EGFR mutants transfected into HEK293 cells and treated with or without D6 (2.5 µM). The numbers 1, 2, and 3 represented indicated EGFR mutants. c Cell lysates derived from HEK293 cells transfected with HA-Ub and indicated EGFR mutants with D6 (2.5 μM) treatment or not were incubated with anti-HA beads. The elution of anti-HA beads was then subjected to immunoblotting analysis. d Schematic diagram showing the generation of osimertinib-resistant PC9 cells (Os-R) from the osimertinib-sensitive parental cells (Os-S). e Os-S or Os-R cells were treated with the indicated concentrations of osimertinib or D6. Cell viability was detected by CCK8 and displayed after normalized to the control. f The representative images showing the cell proliferation of Os-S or Os-R cells exposed to the indicated concentrations of osimertinib or D6 for long-term culture in 6-well plate. Data are presented as mean ± SEM (e), n = 3 biologically independent samples.